Rhythm Pharmaceuticals Announces The New England Journal Of Medicine Publication Of Phase 3 TRANSCEND Trial Results In Acquired Hypothalamic Obesity

(MENAFN - GlobeNewsWire - Nasdaq) BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming ...